We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of ACADIA ...

Charles Schwab Investment Management Inc. lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- ...

Dr. Salvadore is an established industry executive physician and leader with more than 15 years of experience leading ...

ACADIA Pharmaceuticals ACAD has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

Acadia Pharmaceuticals (ACAD) and Saniona announced the completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study of ACP-711, formerly SAN711, in healthy ...